• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least partially reversed in vivo by the immune-modulatory drug lenalidomide 
    •   QMRO Home
    • Barts Cancer Institute
    • Centre for Cancer & Inflammation
    • PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least partially reversed in vivo by the immune-modulatory drug lenalidomide
    •   QMRO Home
    • Barts Cancer Institute
    • Centre for Cancer & Inflammation
    • PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least partially reversed in vivo by the immune-modulatory drug lenalidomide
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    PD-1/PD-L1 mediated T-cell dysfunction in CLL is not absolute and can be at least partially reversed in vivo by the immune-modulatory drug lenalidomide

    Volume
    37
    Pagination
    236 - 236
    Journal
    ONCOLOGY RESEARCH AND TREATMENT
    ISSN
    2296-5270
    Metadata
    Show full item record
    Authors
    McClanahan, F; Riches, JC; Miller, S; Ghazaly, E; Day, W; Capasso, M; Gribben, J
    URI
    http://qmro.qmul.ac.uk/xmlui/handle/123456789/6568
    Collections
    • Centre for Cancer & Inflammation [107]
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.